Generic atypical antipsychotic drugs in Belgium: Their influence and implications

Brian Godman*, Kristien De Bruyn, Jamilette Miranda, Emanuel Raschi, Marion Bennie, Corrado Barbui, Steven Simoens

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Introduction: Generic atypical antipsychotic drugs should be a focus of attention given their expenditure. However, there is a recognized need to tailor treatments. There were no specific measures in Belgium to enhance the prescribing of oral risperidone following generics in January 2008. Prescribing restrictions have remained for long-acting risperidone injections throughout. Objective: Assess changes in risperidone utilization before and after oral generics were reimbursed, as well as the utilization and expenditure of the various risperidone preparations. Method: Principally a retrospective observational study and interrupted time series design. Results: As expected, no increased utilization of oral risperidone after generics. Both originator and generic oral risperidone prescribed, with the originator reducing its price. Generic risperidone was 59% below prepatent loss prices by September 2012. Conclusion: Authorities cannot rely on a 'spill over' of learning from other disease areas to affect changes in physician prescribing habits. Specific measures are needed to encourage generic risperidone where appropriate. However, their influence will be limited by the complexity of the disease area.

Original languageEnglish
Pages (from-to)551-561
Number of pages11
JournalJournal of Comparative Effectiveness Research
Issue number6
Publication statusPublished - Nov 2013
Externally publishedYes


  • Belgium
  • antipsychotics
  • demand-side measures
  • drug utilization
  • generics


Dive into the research topics of 'Generic atypical antipsychotic drugs in Belgium: Their influence and implications'. Together they form a unique fingerprint.

Cite this